bevacizumab

CHEBI:CHEBI_749901

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

generic_name
Bevacizumab
brand_name
Avastin
brand_name_base
Avastin
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20241231
package_marketing_start_date
26-FEB-04
dosage_form
LIQUID
route
INTRAVENOUS
marketing_category
DRUG FOR FURTHER PROCESSING
active_ingredient_strength
400 mg/16mL
labeler_name
Genentech, Inc. (SSF)
manufacturer_name
Genentech, Inc.
nui
N0000178291
pharm_class_epc
Vascular Endothelial Growth Factor Inhibitor [EPC]
pharm_class
Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
pharm_class_moa
Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
product_ndc
50242-160
marketing_start_date
20040226
spl_id
9b93021b-6009-4b50-a190-a760e8af2ab1
active_ingredient_name
BEVACIZUMAB
package_ndc
50242-160-02
package_description
300 L in 1 TANK (50242-160-02)
application_number
BLA125085
unii
2S9ZZM9Q9V
spl_set_id
939b5d1f-9fb2-4499-80ef-0607aa6b114e
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class